

## ACCF Study Session for Maintenance of Certification – Interventional Cardiology Updates 2007 and 2008

### Faculty Disclosure/Conflict of Interest Statement

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC), the American College of Cardiology Foundation (ACCF) must ensure balance, independence, objectivity and scientific rigor in all of their directly sponsored or jointly sponsored educational activities. Provider(s) and faculty participating in a sponsored activity are required to disclose to the audience any significant financial interests or other relationships he/she or a member of their immediate family may have (1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. ACCF is committed to providing its learners with high-quality activities and materials that promote improvements and quality in health care and not a specific proprietary business or commercial interest. The intent of this disclosure is not to prevent participation in sponsored educational activities by persons with a financial or other relationship, but rather to provide learners with information on which they can make their own determination whether financial interests or relationships may influence the credited activity. ACCF assesses conflict of interest (COI) with its faculty, planners, managers, staff and other individuals who are in a position to control the content of CME/CE-credited activities. All relevant potential conflicts of interest that are identified are thoroughly vetted through a process that includes course directors and appropriate peer review by education committee chairs/members, for fair balance, scientific objectivity and validity, and patient care and safety recommendations.

ACCF also requires that all faculty disclose their intent to discuss any unlabeled/unapproved uses of drugs and/or devices during their presentations.

#### Faculty

##### Program Directors

**Joseph D. Babb, MD, FSCAI, FACC**

Nothing to disclose

**James E. Tchong, MD, FACC, FSCAI, FESC**

*Consultant/Consulting Fees/Honoraria (Modest)*

Daiichi Sankyo; Eli Lilly; HeartScape Technologies;  
Medicure Pharmaceuticals; sanofi aventis; Schering  
Plough Research Institute; Scios

*Organizational Disclosures*

McKesson; Philips Healthcare

*Other Financial Relationship or Competing Interest (Modest)*

Orexigen

*Speaker/Speaker's Bureau (Modest)*

GlaxoSmithKline

*Speaker/Speaker's Bureau (Significant)*

sanofi aventis; Schering Plough Research Institute

#### Invited Faculty

**Morton J. Kern, MD, FSCAI, FAHA, FACC**

*Consultant/Consulting Fees/Honoraria (Significant)*

Merit Medical Inc.

*Speaker/Speaker's Bureau (Modest)*

Volcano Therapeutics

*Speaker/Speaker's Bureau (Significant)*

Radi Medical Systems

**David J. Moliterno, MD, FACC, FSCAI**

*Consultant/Consulting Fees/Honoraria (Modest)*

Boston Scientific; Portola Pharmaceuticals; Schering  
Plough

*Organizational Disclosure*

Boston Scientific